Northern Trust
RLMD icon

Northern Trust’s Relmada Therapeutics RLMD Stock Holding History

Northern Trust’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.44M Buy
786,257
+628,523
+398% +$4.39M ﹤0.01% 2574
2026
Q1 		$1.1M Sell
157,734
-7,719
-5% -$36.5K ﹤0.01% 3293
2025
Q4 		$799K Buy
165,453
+106,430
+180% +$357K ﹤0.01% 3475
2025
Q3 		$119K Sell
59,023
-548
-0.9% -$526 ﹤0.01% 4095
2025
Q2 		$35.8K Hold
59,571
– – ﹤0.01% 4285
2025
Q1 		$16.1K Sell
59,571
-24,711
-29% -$8.19K ﹤0.01% 4359
2024
Q4 		$43.8K Buy
84,282
+9,566
+13% +$23.3K ﹤0.01% 4278
2024
Q3 		$242K Sell
74,716
-4,259
-5% -$13.8K ﹤0.01% 3817
2024
Q2 		$237K Sell
78,975
-2,074
-3% -$7.5K ﹤0.01% 3806
2024
Q1 		$377K Sell
81,049
-15,218
-16% -$73.3K ﹤0.01% 3655
2023
Q4 		$399K Buy
96,267
+49,165
+104% +$146K ﹤0.01% 3619
2023
Q3 		$141K Sell
47,102
-348
-0.7% -$1.03K ﹤0.01% 3924
2023
Q2 		$117K Sell
47,450
-162,541
-77% -$449K ﹤0.01% 3995
2023
Q1 		$475K Sell
209,991
-18,358
-8% -$63.3K ﹤0.01% 3488
2022
Q4 		$797K Sell
228,349
-23,128
-9% -$203K ﹤0.01% 3345
2022
Q3 		$9.31M Buy
251,477
+1,406
+0.6% +$39K ﹤0.01% 2024
2022
Q2 		$4.75M Buy
250,071
+4,435
+2% +$96.7K ﹤0.01% 2552
2022
Q1 		$6.63M Buy
245,636
+71,704
+41% +$1.48M ﹤0.01% 2405
2021
Q4 		$3.92M Buy
173,932
+10,727
+7% +$239K ﹤0.01% 2838
2021
Q3 		$4.28M Buy
163,205
+6,807
+4% +$182K ﹤0.01% 2828
2021
Q2 		$5.01M Sell
156,398
-6,296
-4% -$219K ﹤0.01% 2837
2021
Q1 		$5.73M Sell
162,694
-10,274
-6% -$359K ﹤0.01% 2669
2020
Q4 		$5.55M Sell
172,968
-4,050
-2% -$139K ﹤0.01% 2626
2020
Q3 		$6.66M Sell
177,018
-5,305
-3% -$205K ﹤0.01% 2357
2020
Q2 		$8.16M Buy
182,323
+155,710
+585% +$6.58M ﹤0.01% 2224
2020
Q1 		$908K Buy
26,613
+2,332
+10% +$94K ﹤0.01% 3254
2019
Q4 		$947K Buy
+24,281
New +$738K ﹤0.01% 3417

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust's RLMD Position: Q2 2026 in Review

Northern Trust increased its Relmada Therapeutics (RLMD) stake by 398% in Q2 2026, buying an estimated $4.39M and bringing the position to 786,257 shares worth $5.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2574.

Northern Trust first reported a position in RLMD in Q4 2019 and has held it in 27 quarters since. The position peaked at $9.31M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Northern Trust held 786,257 shares of Relmada Therapeutics worth $5.44M as of Q2 2026.
  • Northern Trust bought 628,523 Relmada Therapeutics shares in Q2 2026, an estimated $4.39M.
  • Relmada Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2574 holding.
  • Northern Trust first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Northern Trust's Relmada Therapeutics position peaked at $9.31M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.